EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
19.52
-0.09 (-0.46%)
Real-time:   9:30AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.52 - 19.60
52 week 9.53 - 23.20
Open 19.52
Vol / Avg. 1,000.00/2.54M
Mkt cap 1.74B
P/E     -
Div/yield     -
EPS -0.79
Shares 82.93M
Beta 1.41
Inst. own 97%
Oct 27, 2014
Q3 2014 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 4, 2014
Exact Sciences Corp at Robert W. Baird & Co. Inc Health Care Conference
Aug 25, 2014
Exact Sciences Corp Conference Call to discuss the Mayo Clinic will be the First Health System to offer Cologuard(R)
Aug 13, 2014
Exact Sciences Corp at Canaccord Genuity Growth Conference
Jul 24, 2014
EXACT Sciences Corporation Annual Shareholder Meeting
Jul 22, 2014
Q2 2014 Exact Sciences Corp Earnings Call
Jul 22, 2014
Q2 2014 EXACT Sciences Corporation Earnings Release
Jun 25, 2014
EXACT Sciences Corporation at JMP Securities Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -1122.44%
Operating margin - -1128.40%
EBITD margin - -1094.18%
Return on average assets -39.99% -35.95%
Return on average equity -42.76% -39.77%
Employees 102 -
CDP Score - -

Address

441 Charmany Drive
MADISON, WI 53719
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company�s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company�s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The Company�s Cologuard test includes methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 52
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 59
Bio & Compensation  - Reuters